The combination of hypertension and sexual dysfunction is, in Traditional Chinese Medicine, often linked to a kidney deficiency syndrome, primarily kidney Yin deficiency. Previous research groups' investigations revealed that the Yin-enriching and kidney-tonifying method exhibited positive results in lowering blood pressure, improving sexual function, reversing risk factors, and protecting target organs from damage. In this article, the traditional Chinese medical understanding, modern pathophysiological mechanisms, and clinical treatment approaches for kidney-tonifying drugs (single and compound) in treating hypertension co-morbid with sexual dysfunction were explored systematically, with the objective of establishing a scientific foundation for kidney-tonifying methods in this situation.
Within the orthopaedic and traumatology department, fractures are a common medical issue. Jiegu Qili Tablets (Capsules), a Chinese patent medicine frequently administered for fracture treatment in clinical settings, falls under the category of Class A drugs within the National Medical Insurance System. In contrast to a need for detailed evidence-based guidance, no such consensus exists, therefore severely limiting the practical clinical usefulness of this medicine. A consensus was developed according to the steps stipulated in the expert consensus on clinical applications of proprietary Chinese medicines, with evidence as the core, consensus as a supplementary principle, and experience as the guiding reference. The consensus derived from a literature review and questionnaire survey concerning Jiegu Qili Tablets (Capsules) for fracture treatment was a timely summary of the existing clinical evidence, including the treatment experiences of many seasoned clinical experts. read more The consensus document, GS/CACM 293-2021, was formally released in September 2021 by the China Association of Chinese Medicine. This document, the product of more than a year of preparation, benefited from the expertise of multidisciplinary specialists drawn from 27 organizations spanning Chinese and Western medicine, as well as research institutions. The consensus's background and objectives are explored in this article, which also details the methods of proposal generation, document creation, expert evaluations, and public input. Concerning the clinical application of Jiegu Qili Tablets (Capsules) in fracture treatment, key issues of indications, treatment timing, dosage, duration, and safety have resulted in 5 consensus recommendations and 12 consensus suggestions. These serve to guide and standardize clinical practice, improving the accuracy and safety of drug use.
Within this study, an overview of systematic reviews/meta-analyses (SR/MAs) on the application of Chinese herbal injections for sepsis was performed, in order to guide clinical practice and enhance the standard of clinical evidence. From database inception to June 2022, eight Chinese and English databases, such as CNKI, Medline, and EMbase, were electronically queried for systematic reviews/meta-analyses (SR/MAs) of Chinese herbal injection therapy for sepsis. The combined application of AMSTAR 2, PRISMA 2020, the GRADE system, and the Recommendations for Clinical Evidence Grading on Traditional Chinese Medicine Based on Evidence Body facilitated the evaluation of the methodological quality, reporting quality, and the evidence quality within the included articles. Forty-seven SR/MA studies investigated the effectiveness of four Chinese herbal injections: Xuebijing, Shenfu, Shenmai, and Shengmai. Using the AMSTAR 2 checklist, the methodological quality of the systematic review/meta-analysis was discovered to lie within the moderate to very low quality spectrum. Item 2 (prior study design) garnered significantly low scores, as did less significant items 3 (study design selection reasoning), 10 (description of funding sources), and 16 (disclosure of conflicts of interest). Eight topic areas detailed under PRISMA 2020, demanding complete reporting of missing data greater than 50%, include the search strategy, certainty evaluation, synthesis results, evidence certainty, registration and protocol, support, competing interests, data accessibility, and availability of codes and additional materials. The SR/MA, which was included, encompassed 30 outcome indicators. The quality of mortality, APACHE score, and safety, the primary outcome indicators, were evaluated, and all were categorized as medium. Insufficient allocation concealment, a lack of blinding, along with a missing randomized allocation sequence and inadequate trial sample size, collectively resulted in a lower evidence level. Studies suggest that Chinese herbal injections can be a secure and effective adjunct to standard sepsis treatment, leading to decreased mortality, reduced inflammation, improved blood clotting, and balanced immune function, tissue perfusion, and oxygenation in sepsis patients. Although the quality of SR/MA data was not up to par, further high-quality SR/MA studies are crucial to demonstrating the efficacy and safety of Chinese herbal injections in sepsis.
This investigation meticulously explored the therapeutic and adverse effects of the Fengliao Changweikang prescription for acute gastroenteritis (AGE). Plant biology A meticulous search across CNKI, Wanfang, VIP, SinoMed, Medline, the Cochrane Library, and two clinical trial registration platforms was executed, spanning from their initial records to August 30, 2022, to locate randomized controlled trials (RCTs) investigating the impact of Fengliao Changweikang on AGE. Two researchers independently conducted the literature review, data extraction, and risk of bias evaluation, according to pre-determined inclusion and exclusion criteria. Data analysis was facilitated by the application RevMan 54.1. Ultimately, eighteen randomized controlled trials were selected, comprising 3,489 patients. Further, the Fengliao Changweikang prescription demonstrated a reduction in the levels of IL-8 (RR = -107, 95%CI[-126,-088],P<0.00001), IL-6 (RR = -824, 95%CI[-899,-749],P<0.00001) and hs-CRP (RR=-304, 95%CI[-340,-269],P<0.00001) when compared to Western medicine alone. To summarize, the Fengliao Changweikang prescription proved safe during clinical use. The clinical presentation of diarrhea, abdominal pain, vomiting, and fever in AGE patients was improved, accompanied by a decrease in certain serum inflammatory factors, showcasing a beneficial impact. Considering the scarcity of robust studies evaluating the Fengliao Changweikang prescription's efficacy and safety in treating AGE, a need for further exploration is evident.
This research sought to delineate pharmacokinetic and tissue distribution disparities for four alkaloids across Ermiao Pills and Sanmiao Pills, considering normal and arthritic rat models. Employing Freund's complete adjuvant, a rat arthritis model was created. Subsequently, ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) in positive ion multiple reaction monitoring (MRM) mode was used to determine four alkaloids in the plasma and tissues of normal and arthritic rats after administration of Ermiao Pills and Sanmiao Pills, respectively. The research compared the pharmacokinetics and tissue distribution of the four active ingredients, and further evaluated the impact of Achyranthis Bidentatae Radix on the main components found within Sanmiao Pills. This study introduced an UPLC-MS/MS method capable of simultaneously determining four alkaloids, with the method's metrics for specificity, linearity, accuracy, precision, and stability satisfying the required parameters. The pharmacokinetic study in model rats, in comparison to normal rats, found a substantial decrease in AUC and Cmax values for phellodendrine, magnoflorine, berberine, and palmatine after Ermiao Pill administration. A significant increase in clearance rate (CL/F) was observed, and a significant reduction was seen in tissue/plasma concentration ratios for the four alkaloids across the liver, kidneys, and joints. Following treatment with Achyranthis Bidentatae Radix, there was an enhancement of the area under the curve (AUC) of phellodendrine, berberine, and palmatine, accompanied by a reduction in their clearance, and a significant increase in their distribution to the liver, kidney, and joints in arthritic rats. Nonetheless, the pharmacokinetics and tissue distribution of the four alkaloids remained unaffected in normal rats. Arthritis states appear to be influenced by Achyranthis Bidentatae Radix within Sanmiao Pills, potentially via increased tissue distribution of its active components, suggesting a possible guiding role in meridian pathways.
Precious Chinese medicine Dendrobii Caulis boasts Gigantol, a phenolic constituent, with numerous pharmacological applications, including tumor prevention and the management of diabetic cataracts. In this paper, we investigated how gigantol impacts transmembrane transport at the molecular level within human lens epithelial cells (HLECs). Cultured immortalized HLECs were transferred to laser scanning confocal microscopy (LSCM) media, with a cell density of 5,000 per milliliter. In HLECs, fluorescence intensity and distribution of gigantol, marked by fluorescence, were assessed using LSCM. The quantified fluorescence intensity depicted the absorption and distribution profile of gigantol. An examination of how gigantol moves across the membrane in HLECs was performed. The transmembrane absorption and transport of gigantol, in response to variations in time, temperature, concentration, transport inhibitors, and diverse cell lines, were compared and contrasted. Utilizing 6-well culture plates, HLECs were grown on their climbing surfaces, and the ultrastructure of the HLECs was elucidated via atomic force microscopy (AFM) during their transmembrane absorption of non-fluorescently labeled gigantol. quinoline-degrading bioreactor The findings indicated a temporal and concentration-dependent transmembrane absorption of gigantol, highlighting its specific targeting of HLECs.